Evidence map›Paper›PMID 36806558›Full record

ArticleBlood advances2023

Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.

Saveria Mazzara, Laura Travaini, Francesca Botta, Chiara Granata, Giovanna Motta, Federica Melle, Stefano Fiori, Valentina Tabanelli, Anna Vanazzi, Safaa Ramadan and 9 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Saveria MazzaraHaematopathology Division, European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Laura TravainiNuclear Medicine Division, IEO IRCCS, Milan, Italy.
Francesca BottaMedical Physics Unit, IEO IRCCS, Milan, Italy.
Chiara GranataOncohematology Division, IEO IRCCS, Milan, Italy.
Giovanna MottaHaematopathology Division, European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.ORCID 0000-0001-5593-5397
Federica MelleHaematopathology Division, European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Stefano FioriHaematopathology Division, European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Valentina TabanelliHaematopathology Division, European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.ORCID 0000-0002-4142-2248
Anna VanazziOncohematology Division, IEO IRCCS, Milan, Italy.ORCID 0000-0002-2977-4208
Safaa RamadanOncohematology Division, IEO IRCCS, Milan, Italy.
Tommaso RadiceOncohematology Division, IEO IRCCS, Milan, Italy.
Sara RaimondiMolecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO IRCCS, Milan, Italy.ORCID 0000-0003-4673-9049
Giuliana Lo PrestiMolecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO IRCCS, Milan, Italy.ORCID 0000-0003-4023-2589
Mahila E FerrariMedical Physics Unit, IEO IRCCS, Milan, Italy.ORCID 0000-0002-4373-8588
Barbara Alicja Jereczek-FossaDivision of Radiation Oncology, IEO IRCCS, Milan, Italy.
Corrado TarellaOncohematology Division, IEO IRCCS, Milan, Italy.
Francesco CeciNuclear Medicine Division, IEO IRCCS, Milan, Italy.ORCID 0000-0001-9785-5248
Stefano PileriHaematopathology Division, European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.ORCID 0000-0001-8032-5128
Enrico DerenziniOncohematology Division, IEO IRCCS, Milan, Italy.ORCID 0000-0002-7154-8140
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Milan · ITIGEA Clinical Biophysics (Italy) · ITCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence indicates that chemoresistance is closely related to altered metabolism in cancer. Here, we hypothesized that distinct metabolic gene expression profiling (GEP) signatures might be correlated with outcome and with specific fluorodeoxyglucose positron emission tomography (FDG-PET) radiomic profiles in diffuse large B-cell lymphoma (DLBCL). We retrospectively analyzed a discovery cohort of 48 consecutive patients with DLBCL treated at our center with standard first-line chemoimmunotherapy by performing targeted GEP (T-GEP)- and FDG-PET radiomic analyses on the same target lesions at baseline. T-GEP-based metabolic profiling identified a 6-gene signature independently associated with outcomes in univariate and multivariate analyses. This signature included genes regulating mitochondrial oxidative metabolism (SCL25A1, PDK4, PDPR) that were upregulated and was inversely associated with genes involved in hypoxia and glycolysis (MAP2K1, HIF1A, GBE1) that were downregulated. These data were validated in 2 large publicly available cohorts. By integrating FDG-PET radiomics and T-GEP, we identified a radiometabolic signature (RadSig) including 4 radiomic features (histo kurtosis, histo energy, shape sphericity, and neighboring gray level dependence matrix contrast), significantly associated with the metabolic GEP-based signature (r = 0.43, P = .0027) and with progression-free survival (P = .028). These results were confirmed using different target lesions, an alternative segmentation method, and were validated in an independent cohort of 64 patients. RadSig retained independent prognostic value in relation to the International Prognostic Index score and metabolic tumor volume (MTV). Integration of RadSig and MTV further refined prognostic stratification. This study provides the proof of principle for the use of FDG-PET radiomics as a tool for noninvasive assessment of cancer metabolism and prognostic stratification in DLBCL.

Indexed as

Fluorodeoxyglucose F18Lymphoma, Large B-Cell, DiffuseGene Expression ProfilingHumansPositron-Emission TomographyRetrospective StudiesFluorodeoxyglucose F18

Identifiers

PMID36806558
PMCPMC9979764
OpenAlexW4321445487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.